Development Pipeline

 DiscoveryPreclinicalPhase 1Phase 2Phase 3
 Discovery Preclinical Phase 1 Phase 2 Phase 3
ACH-3102NS5A Inhibitor    
ACH-3422Nucleotide NS5B Polymerase Inhibitor   
SovaprevirNS3/4A Protease Inhibitor    
ACH-CFDIsComplement Factor D Inhibitors 

About Achillion

Headquartered in New Haven, CT,Achillion applies expertise in biology and structure-guided design and a deep understanding of patient and clinician needs to develop innovative treatment solutions aimed at improving the lives of patients. More...

HCV Education

About the Hepatitis C Virus

Hepatitis C is a worldwide epidemic affecting more than 150 million individuals. Click to learn more about this disease.

You are now leaving this website. If you would like to continue, click Continue.